Novel cannabinoid receptors

British Journal of Pharmacology

Volumn 152, Issue 5, 2007, Pages 567-575

  Brown, A J ^a  

^a GLAXOSMITHKLINE   (United Kingdom)

Author keywords

Cannabinoid; CB 1; CB 2; GPR119; GPR55; Non CB 1 CB 2

Indexed keywords

1 (2,4 DICHLOROPHENYL) 5 (4 IODOPHENYL) 4 METHYL N (1 PIPERIDYL) 1H PYRAZOLE 3 CARBOXAMIDE; 1 DEOXY 3 (1,1 DIMETHYLBUTYL) DELTA8 TETRAHYDROCANNABINOL; 2 ARACHIDONOYLGLYCEROL; 2 METHYL 3 (1 NAPHTHOYL) 1 PROPYLINDOLE; 2,3 DIHYDRO 5 METHYL 3 (MORPHOLINOMETHYL) 6 (1 NAPHTHOYL)PYRROLO[1,2,3 DE][1,4]BENZOXAZINE; 4 (1,1 DIMETHYLHEPTYL) 1',2',3',4',5',6' HEXAHYDRO 2,3' DIHYDROXY 6' (3 HYDROXYPROPYL)BIPHENYL; 5 (4 CHLORO 3 METHYLPHENYL) 1 (4 METHYLBENZYL) N (1,3,3 TRIMETHYLBICYCLO[2.2.1]HEPTAN 2 YL) 3 PYRAZOLECARBOXAMIDE; CANNABIDIOL; CANNABINOID 1 RECEPTOR; CANNABINOID 2 RECEPTOR; CANNABINOID RECEPTOR; CANNABINOID RECEPTOR AGONIST; CANNABINOID RECEPTOR ANTAGONIST; CANNABINOL; DEXANABINOL; ENDOCANNABINOID; G PROTEIN COUPLED RECEPTOR; G PROTEIN COUPLED RECEPTOR 119; G PROTEIN COUPLED RECEPTOR 55; GUANOSINE 5' O (3 THIOTRIPHOSPHATE); METHANANDAMIDE; N OLEOYLETHANOLAMINE; O 1602; ORPHAN DRUG; PALMIDROL; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR AGONIST; RIMONABANT; SILDENAFIL; TETRAHYDROCANNABINOLIC ACID; UNCLASSIFIED DRUG; UNINDEXED DRUG; VIRODHAMINE;

CENTRAL NERVOUS SYSTEM; HUMAN; IMMUNOCOMPETENT CELL; NONHUMAN; PHYLOGENETIC TREE; PRIORITY JOURNAL; REVIEW; VASCULARIZATION;

ANIMALS; CANNABINOIDS; HUMANS; PHYLOGENY; RECEPTORS, CANNABINOID; RECEPTORS, G-PROTEIN-COUPLED;

EID: 35748973885     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1038/sj.bjp.0707481     Document Type: Review

References (64)

1. Baker D, Pryce G, Davies WL, Hiley CR (2006). In silico patent searching reveals a new cannabinoid receptor. Trends Pharmacol Sci 27: 1-4.
2. + current. J Biol Chem 278: 46188-46194.
3. Begg M, Pacher P, Batkai S, Osei-Hyiaman D, Offertaler L, Mo FM et al. (2005). Evidence for novel cannabinoid receptors. Pharmacol Ther 106: 133-145.
4. Bocher V, Pineda-Torra I, Fruchart JC, Staels B (2002). PPARs: transcription factors controlling lipid and lipoprotein metabolism. Ann NY Acad Sci 967: 7-18.
5. Breivogel CS, Griffin G, Di Marzo V, Martin BR (2001). Evidence for a new G protein-coupled cannabinoid receptor in mouse brain. Mol Pharmacol 60: 155-163.
6. Brown AJ, Dyos SL, Whiteway MS, White JHM, Watson M-A, Marzioch M et al. (2000). Functional coupling of mammalian receptors to the yeast mating pathway using novel yeast/mammalian G protein α-subunit chimeras. Yeast 16: 11-22.
7. Brown AJ, Wise A (2001). Identification of modulators of GPR55 activity. Assignee: GlaxoSmithKline. Patent WO00186305.
8. Buckley NE, McCoy KL, Mezey E, Bonner T, Zimmer A, Felder CC et al. (2000). Immunomodulation by cannabinoids is absent in mice deficient for the cannabinoid CB(2) receptor. Eur J Pharmacol 396: 141-149.
9. Calignano A, La Rana G, Giuffrida A, Piomelli D (1998). Control of pain initiation by endogenous cannabinoids. Nature 394: 277-281.
10. Cheng Y, Hitchcock SA (2007). Targeting cannabinoid agonists for inflammatory and neuropathic pain. Expert Opin Investig Drugs 16: 951-965.
11. Chinetti G, Fruchart JC, Staels B (2000). Peroxisome proliferator- activated receptors (PPARs): nuclear receptors at the crossroads between lipid metabolism and inflammation. Inflamm Res 49: 497-505.
12. 2 cannabinoid receptors are implicated in inflammatory pain. Pain 96: 253-260.
13. Dowell SJ, Brown AJ (2002). Yeast assays for G-protein-coupled receptors. Receptors Channels 8: 343-352.
14. Drmota E, Greasley P, Groblewski T (2004). Screening assays for cannabinoid-ligand type modulators. Assignee: AstraZeneca. Patent WO2004074844.
15. 2 receptor activation inhibits mechanically evoked responses of wide dynamic range dorsal horn neurons in naive rats and in rat models of inflammatory and neuropathic pain. Eur J Neurosci 20: 2311-2320.
16. Foord SM (2007). G protein-coupled receptors and comparative genomics. In: Brown JA (ed), Comparative Genomics: Basic and Applied Research. Taylor & Francis: Boca Raton, pp 283-300.
17. Fredriksson R, Hoglund PJ, Gloriam DEI, Lagerstrom MC, Schioth HB (2003). Seven evolutionarily conserved human rhodopsin G protein-coupled receptors lacking close relatives. FEBS Lett 554: 381-388.
18. Fu J, Astarita G, Gaetani S, Kim J, Cravatt BF, Mackie K et al. (2007). Food intake regulates oleoylethanolamide formation and degradation in the proximal small intestine. J Biol Chem 282: 1518-1528.
19. Fu J, Gaetani S, Oveisi F, Lo Verme J, Serrano A, Rodriguez de Fonseca F et al. (2003). Oleoylethanolamide regulates feeding and body weight through activation of the nuclear receptor PPAR-[alpha]. Nature 425: 90-93.
20. Fujiwara Y, Sardar V, Tokumura A, Baker D, Murakami-Murofushi K, Parrill A et al. (2005). Identification of residues responsible for ligand recognition and regioisomeric selectivity of lysophosphatidic acid receptors expressed in mammalian cells. J Biol Chem 280: 35038-35050.
21. 2 receptor agonist for the treatment of inflammatory pain. J Med Chem 50: 2597-2600.
22. Hajos N, Ledent C, Freund TF (2001). Novel cannabinoid-sensitive receptor mediates inhibition of glutamatergic synaptic transmission in the hippocampus. Neuroscience 106: 1-4.
23. 1-specific agents. Behav Pharmacol 15: 299-304.
24. Hata AN, Lybrand TP, Breyer RM (2005). Identification of determinants of ligand binding affinity and selectivity in the prostaglandin D2 receptor CRTH2. J Biol Chem 280: 32442-32451.
25. Hiley CR, Kaup SS (2007). GPR55 and the vascular receptor for cannabinoids. Br J Pharmacol; [e-pub ahead of print: 20 August 2007; doi:10.1038/sj.bjp.0707421].
26. Hirai H, Tanaka K, Yoshie O, Ogawa K, Kenmotsu K, Takamori Y et al. (2001). Prostaglandin D2 selectively induces chemotaxis in T helper type 2 cells, eosinophils, and basophils via seven-transmembrane receptor CRTH2. J Exp Med 193: 255-262.
27. 2 cannabinoid receptors by AM1241 inhibits experimental neuropathic pain: pain inhibition by receptors not present in the CNS. Proc Natl Acad Sci USA 100: 10529-10533.
28. 2 receptor agonist palmitoylethanolamide in visceral and somatic inflammatory pain. Pain 76: 189-199.
29. 2 receptors. Proc Natl Acad Sci USA 96: 14136-14141.
30. Johns DG, Behm DJ, Walker D, Ao Z, Parsons M, Daniels D et al. (2007). The novel endocannabinoid receptor GPR55 binds atypical cannabinoids but does not mediate their vasodilatory effects. Br J Pharmacol; [e-pub ahead of print: 20 August 2007; doi:10.1038/sj.bjp.0707419].
31. Jones R (2006). Discovery of agonists of the glucose dependent insulinotropic receptor, GPR119, a pancreatic beta-cell oGPCR, for the treatment of NIDDM. Drugs Future 31 (Suppl A). Abstract L48.
32. Kabarowski JHS, Zhu K, Le LQ, Witte ON, Xu Y (2001). Lysophosphatidylcholine as a ligand for the immunoregulatory receptor G2A. Science 293: 702-705.
33. Klein TW (2005). Cannabinoid-based drugs as anti-inflammatory therapeutics. Nat Rev Immunol 5: 400-411.
34. Kraft B, Wintersberger W, Kress HG (2004). Cannabinoid receptor-independent suppression of the superoxide generation of human neutrophils (PMN) by CP55940, but not by anandamide. Life Sci 75: 969-977.
35. Lee CW, Rivera R, Gardell S, Dubin AE, Chun J (2006). GPR92 as a new G12/13- and Gq-coupled lysophosphatidic acid receptor that increases cAMP, LPA5. J Biol Chem 281: 23589-23597.
36. Lee DL, Webb RC, Jin LM (2004). Hypertension and RhoA/Rho-kinase signaling in the vasculature - highlights from the recent literature. Hypertension 44: 796-799.
37. Lo Verme J, Fu J, Astarita G, La Rana G, Russo R, Calignano A et al. (2005a). The nuclear receptor peroxisome proliferator-activated receptor-alpha mediates the anti-inflammatory actions of palmitoylethanolamide. Mol Pharmacol 67: 15-19.
38. Lo Verme J, La Rana G, Russo R, Calignano A, Piomelli D (2005b). The search for the palmitoylethanolamide receptor. Life Sci 77: 1685-1698.
39. Mackie K, Stella N (2007). Cannabinoid receptors and endocannabinoids: evidence for new players. AAPS J 8: E298-E306.
40. Massi P, Vaccani A, Parolaro D (2006). Cannabinoids, immune system and cytokine network. Curr Pharm Des 12: 3135-3146.
41. McPartland JM, Matias I, Di Marzo V, Glass M (2006). Evolutionary origins of the endocannabinoid system. Gene 370: 64-74.
42. Mechoulam R, Parker LA, Gallily R (2002). Cannabidiol: an overview of some pharmacological aspects. J Clin Pharmacol 42: 11S-19S.
43. Nielsen MJ, Petersen G, Astrup A, Hansen HS (2004). Food intake is inhibited by oral oleoylethanolamide. J Lipid Res 45: 1027-1029.
44. Noguchi K, Ishii S, Shimizu T (2003). Identification of p2y9/GPR23 as a novel G protein-coupled receptor for lysophosphatidic acid, structurally distant from the EDG family. J Biol Chem 278: 25600-25606.
45. O'Sullivan SE, Kendall DA, Randall MD (2005). The effects of Delta(9)-tetrahydrocannabinol in rat mesenteric vasculature, and its interactions with the endocannabinoid anandamide. Br J Pharmacol 145: 514-526.
46. Obinata H, Hattori T, Nakane S, Tatei K, Izumi T (2005). Identification of 9-hydroxyoctadecadienoic acid and other oxidized free fatty acids as ligands of the G protein-coupled receptor G2A. J Biol Chem 280: 40676-40683.
47. Offertaler L, Mo FM, Batkai S, Liu J, Begg M, Razdan RK et al. (2003). Selective ligands and cellular effectors of a G protein-coupled endothelial cannabinoid receptor. Mol Pharmacol 63: 699-705.
48. Overton HA, Babbs AJ, Doel SM, Fyfe MCT, Gardner LS, Griffin G et al. (2006). Deorphanization of a G protein-coupled receptor for oleoylethanolamide and its use in the discovery of small-molecule hypophagic agents. Cell Metab 3: 167-175.
49. Pacher P, Batkai S, Kunos G (2006). The endocannabinoid system as an emerging target of pharmacotherapy. Pharmacol Rev 58: 389-462.
50. Rao GK, Kaminski NE (2006). Cannabinoid-mediated elevation of intracellular calcium: a structure-activity relationship. J Pharmacol Exp Ther 317: 820-829.
51. Riobo NA, Manning DR (2005). Receptors coupled to heterotrimeric G proteins of the G12 family. Trends Pharmacol Sci 26: 146-154.
52. Rockwell CE, Snider NT, Thompson JT, Vanden Heuvel JP, Kaminski NE (2006). Interleukin-2 suppression by 2-arachidonyl glycerol is mediated through peroxisome proliferator-activated receptor gamma independently of cannabinoid receptors 1 and 2. Mol Pharmacol 70: 101-111.
53. Rodriguez de Fonseca F, Navarro M, Gomez R, Escuredo L, Nava F, Fu J et al. (2001). An anorexic lipid mediator regulated by feeding. Nature 414: 209-212.
54. Russo R, LoVerme J, La Rana G, D'Agostino G, Sasso O, Calignano A et al. (2007). Synergistic antinociception by the cannabinoid receptor agonist anandamide and the PPAR-alpha receptor agonist GW7647. Eur J Pharmacol 566: 117-119.
55. Sakamoto Y, Inoue H, Kawakami S, Miyawaki K, Miyamoto T, Mizuta K et al. (2006). Expression and distribution of Gpr119 in the pancreatic islets of mice and rats: predominant localization in pancreatic polypeptide-secreting PP-cells. Biochem Biophys Res Commun 351: 474-480.
56. Sawzdargo M, George SR, Nguyen T, Xu SJ, Kolakowski LF (1997). A cluster of four novel human g protein-coupled receptor genes occurring in close proximity to cd22 gene on chromosome 19q13.1. Biochem Biophys Res Commun 239: 543-547.
57. Soga T, Ohishi T, Matsui T, Saito T, Matsumoto M, Takasaki J et al. (2005). Lysophosphatidylcholine enhances glucose-dependent insulin secretion via an orphan G-protein-coupled receptor. Biochem Biophys Res Commun 326: 744-751.
58. Starowicz K, Nigam S, Di Marzo V (2007). Biochemistry and pharmacology of endovanilloids. Pharmacol Ther 114: 13-33.
59. Staton PC, Hatcher JP, Morrison AD, Walker DJ, Parsons M, Brown AJ et al. (2006). Determining the role of a third cannabinoid receptor, GPR55, in inflammatory and neuropathic pain. 16th ICRS Annual Symposium on the Cannabinoids; 24-28 June 2006; Hungary. ICRS: Hungary. Abstract 149.
60. Taniguchi Y, Tonai-Kachi H, Shinjo K (2006). Zaprinast, a well-known cyclic guanosine monophosphate-specific phosphodiesterase inhibitor, is an agonist for GPR35. FEBS Lett 580: 5003-5008.
61. Wang J, Simonavicius N, Wu X, Swaminath G, Reagan J, Tian H et al. (2006). Kynurenic acid as a ligand for orphan G protein-coupled receptor GPR35. J Biol Chem 281: 22021-22028.
62. Witte ON, Kabarowski JH, Xu Y, Le LQ, Zhu K (2005). Retraction. Science 307: 206b.
63. 1 receptor knockout mice. Proc Natl Acad Sci USA 96: 5780-5785.
64. 2. Immunogenetics 58: 714-725.